Update on the listing of ISR Immune System Regulat
Post# of 301275
Referring to a press releases published by ISR Immune System Regulation Holding AB (the “Company”) on February 24, 2017, the Exchange has decided to initiate an additional, limited review of the Company.
For further clarification, the listing will be conditional upon amendments to the company description of the Company.
Nasdaq Stockholm AB will in due time publish a separate exchange notice with a new date for first day of trading.
For further information concerning this exchange notice please contact Issuer Surveillance, telephone +46 8 405 60 00.